Videos

Rethink trial design with decentralized, community-based models to cut barriers, let patients enroll closer to home, and preserve high-quality safety data.

Ashley Rosko, MD, discusses how telehealth can improve access to myeloma transplant evaluation, reduce care disparities, and address implementation barriers.

Dr Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.

In this episode of The OncoloGIST, myeloma experts discuss the abstracts they most anticipated at IMS 2026, including EXCALIBER-RRMM and PERSEUS.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, compares subcutaneous amivantamab with 2 other EGFR-directed bispecific antibodies advancing toward phase 3 readouts in head and neck squamous cell carcinoma (HNSCC): petosemtamab and ficerafusp alfa.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses what the durability data from OrigAMI-4 cohort 1 suggest about subcutaneous amivantamab's benefit in recurrent or metastatic head and neck squamous cell carcinoma.

Al-Ola Abdallah, MD, discusses IMiD-based holding therapy before leukapheresis and its safety in patients with myeloma receiving CAR T-cell therapy.

Explore why some patients with multiple myeloma miss stem cell transplant, spotlighting age, race and socioeconomic barriers, plus community–tertiary partnerships to expand access.

Alicia Morgans, MD, explains how the ARACOG trial showed higher cognitive decline with enzalutamide vs darolutamide in advanced prostate cancer.

Paula Rodriguez-Otero, MD, discusses how T-cell–engaging therapies are aiming to meaningfully impact or negate the disease course of high-risk smoldering myeloma.

Learn how community oncologists expand clinical trial access, strengthen safety monitoring, and offer patients nearby investigational therapies and more treatment options.

Bispecific antibodies, CAR T therapy, and targeted drugs transform non-Hodgkin lymphoma care, with earlier use and MRD-guided strategies poised to boost outcomes.

Alicia Morgans, MD, MPH, discusses quality-of-life analyses from the ARANOTE and ARASENS trials in metastatic hormone-sensitive prostate cancer.

Dr. Jason Mouabbi discusses remaining unmet needs and practical considerations in the management of PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi discusses how available pathway-directed treatment approaches may be differentiated for patients with biomarker-selected HR-positive/HER2-negative advanced breast cancer, with consideration of treatment setting and toxicity profiles.

Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back pain after 3 months of treatment.

Dr. Jason Mouabbi discusses how to approach adverse-event attribution when treating patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer with a multidrug regimen.

Dr. Jason Mouabbi discusses additional adverse events that require attention when managing patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer receiving combination therapy.

Dr. Jason Mouabbi revisits the patient's Grade 2 hyperglycemia at week 6, when fasting glucose reaches 212 mg/dL.

Dr. Jason Mouabbi discusses the approach to managing treatment-related hyperglycemia while maintaining cancer treatment for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi reviews the treatment initiation and early glucose monitoring strategy for a patient with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer receiving inavolisib in combination with palbociclib and fulvestrant.

Dr. Jason Mouabbi discusses strategies for assessing and managing the risk of treatment-related hyperglycemia before initiating therapy for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi presents a 59-year-old postmenopausal woman with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer who develops metastatic disease 8 months after completing adjuvant endocrine therapy.

Theodore Wagener, PhD, discusses psychedelics beyond depression in cancer, including neuropathy and chemo brain, and why he expects cancer centers to adopt them.

Theodore Wagener, PhD, discusses an Ohio State feasibility study testing psilocybin-assisted therapy for depression in patients with non–small cell lung cancer.

Allogeneic and in vivo CAR T therapies simplify manufacturing and delivery, potentially expanding access to cellular therapy beyond specialized centers.

Amer M. Zeidan, MBBS, MHS, on how genetics, comorbidities, and goals of care guide acute myeloid leukemia treatment selection in real-world practice.

CLL care shifts to targeted combinations, confronting BTK resistance with next-gen inhibitors, degraders, and BCL2 drugs, while CAR T and pivotal trials reshape strategy.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, reviews efficacy results from the fully enrolled cohort 1 of the phase 1b/2 OrigAMI-4 study, published in the Journal of Clinical Oncology in 2026.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, outlines the design of the phase 1b/2 OrigAMI-4 study, an umbrella trial evaluating subcutaneous amivantamab across multiple settings in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), including first-line disease, platinum-refractory disease, and platinum-and-immune-checkpoint-inhibitor (ICI)-refractory disease.